Celyad Oncology (XBRU:CYAD) EV-to-EBITDA : -0.65 (As of May. 01, 2024)

Celyad Oncology EV-to-EBITDA Chart

Celyad Oncology Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBITDA		Get a 7-Day Free Trial					-4.14	-3.78	-5.27	-2.10	0.02

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
EV-to-EBITDA	Get a 7-Day Free Trial															-2.10	-1.20	-1.06	0.02	-

Competitive Comparison of Celyad Oncology's EV-to-EBITDA

For the Biotechnology subindustry, Celyad Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's EV-to-EBITDA falls into.

Celyad Oncology EV-to-EBITDA Calculation

Celyad Oncology's EV-to-EBITDA for today is calculated as:

Celyad Oncology's current Enterprise Value is €9.02 Mil.
Celyad Oncology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology  (XBRU:CYAD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Celyad Oncology's PE Ratio for today is calculated as:

Celyad Oncology's share price for today is €0.325.
Celyad Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.620.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Celyad Oncology EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description